FDA Approves First CAR T-Cell Therapy for rrCLL, rrSLL FDA Approves First CAR T-Cell Therapy for rrCLL, rrSLL

The accelerated approval for liso-cel was based on findings showing 20% of patients achieved a complete response from a one-time infusion after at least two prior lines of therapy.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news